Impact of anxiety and depression disorders on adherence to anticoagulant therapy among patients with atrial fibrillation

Aim. To determine the possible impact of anxiety and depression disorders on the adherence of patients with atrial fibrillation (AF) to anticoagulant the rapy.

Material and methods. The study included outpatients with AF of any type. After signing the informed consent, patients filled out questionnaires and scales that determined the level of anxiety and personal predisposition (MMAS-8, MMAS-4, SF-36, SHAI, STAI, HADS, NEO-FFI).

Results. A total of 117 outpatients treated for AF were included. The mean age of patients was 74±5 years (men, 38%). Based on MMAS-4 and MMAS-8 results, adherent and non-adherent cohorts of patients were formed. Low adherence group had significantly higher situational anxiety according to STAI (45,9±9,9 vs 41,1±10,7, p=0,045) and depression according to HADS (7,9±3,6 vs 5,9±3,5, p=0,018). SF 36 showed that non-adherent patients had a lower general health (41,6±12,9 vs 52,2±20,0, p=0,01). Five-factor model revealed an association between low compliance and low extraversion (21,3±6,6 vs 26,4±7,2, p=0,002). Pharmacokinetic data on blood concentrations of anticoagulants or its metabolites at the second visit were available in 76 (67%) patients. Assessment of pharmacokinetic and compliance data revealed a moderate direct correlation (Matthews correlation coefficient (MCC), 0,345) and a weak direct correlation with the MMAS-8 (MCC, 0,177). The difference in MMAS-4 and MMAS-8 scores between high and low pharmacokinetic adherence groups was significant on both scales (p=0,011 and 0,015, respectively).

Conclusion. The rationale for widespread introduction of standardized questionnaires and scales (MMAS 4, MMAS 8, STAI, HADS, SF 36, Big 5) was shown in order to early identify patients with low adherence to treatment. The results highlight the need for further study of the contribution of psychiatric disorders to low compliance to anticoagulant therapy.

1. Baumgartner C, Fan D, Fang MC, et al. Anxiety, Depression, and Adverse Clinical Outcomes in Patients With Atrial Fibrillation Starting Warfarin: Cardiovascular Research Network WAVE Study. J Am Heart Assoc. 2018;7(8):e007814. doi:10.1161/JAHA.117.007814.

2. Algalarrondo V, Extramiana F. Épidémiologie et physiopathologie de la fibrillation atriale [Epidemiology and pathophysiology of atrial fibrillation]. Rev Prat. 2020;70(8):894-8. French.

3. Jame S, Barnes G. Stroke and thromboembolism prevention in atrial fibrillation. Heart. 2020;106(1):10-7. doi:10.1136/heartjnl-2019-314898.

4. Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2017;117(2):209-18. doi:10.1160/TH16-10-0757.

5. Volel BA, Troshina DV, Fomicheva AV, et al. Impact of mental disorders on adherence to therapy in patients with atrial fibrillation. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2020;13(6):530-8. (In Russ.) doi:10.17116/kardio202013061530.

6. Hindricks G, Potpara T, Dagres N, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collabora tion with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612. Erratum in: Eur Hear J. 2021;42(5):507. Erratum in: Eur Heart J. 2021;42(5):5467. Erratum in: Eur Heart J. 2021;42(40):4194.

7. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74. doi:10.1097/00005650198601000-00007.

8. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305(6846):160-4. doi:10.1136/bmj.305.6846.160.

9. Salkovskis PM, Rimes KA, Warwick HM, Clark DM. The Health Anxiety Inventory: development and validation of scales for the measurement of health anxiety and hypochondriasis. Psychol Med. 2002;32(5):843-53. doi:10.1017/s0033291702005822.

10. Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes. 2003;1:29. doi:10.1186/1477-7525-1-29.

11. Denissen JJA, Geenen R, van Aken MAG, et al. Development and validation of a Dutch translation of the Big Five Inventory (BFI). Journal of personality assessment. 2008; 90(2):152-7.

12. Bauer LK, Caro MA, Beach SR, et al. Effects of depression and anxiety improvement on adherence to medication and health behaviors in recently hospitalized cardiac patients. Am J Cardiol. 2012;109(9):1266-71. doi:10.1016/j.amjcard.2011.12.017.

13. Hart RP, Ball JD, Stutts ML, et al. Correlations for scores on the 180-item version of the MMPI-2 and the Neuroticism scale of the NEO-Personality Inventory. Psychol Rep. 2002;90(1):227-30. doi:10.2466/pr0.2002.90.1.227.